Previous 10 | Next 10 |
2023-08-02 17:11:57 ET Glaukos press release ( NYSE: GKOS ): Q2 Non-GAAP EPS of -$0.55 beats by $0.01 . Revenue of $80.4M (+10.6% Y/Y) beats by $5.74M . For further details see: Glaukos Non-GAAP EPS of -$0.55 beats by $0.01, revenue of $80.4M beats by $5.74M
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2023. Key highlights include: ...
2023-07-17 10:46:36 ET An ophthalmic medical technology and pharmaceutical company, Glaukos ( NYSE: GKOS ) has entered into a collaboration and marketing agreement with Radius XR, whereby Glaukos will become the exclusive sales agent to market, promote, and solicit orders f...
Advancing Next-Generation Wearable Patient Engagement and Diagnostic Technology Designed to Enable More Efficient Detection of Eye Diseases Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glauc...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2023 fin...
2023-06-16 06:13:55 ET Summary Glaukos Corporation has 3 catalysts to price change going forward. These involve the company's performance, growth, and potential future developments. Revising to buy on fundamental, sentimental grounds. Summary of updated investment th...
2023-06-08 14:19:02 ET A regional Medicare contractor in the Southeast has issued a draft policy to cover medical devices marketed by Glaukos Corporation ( NYSE: GKOS ) to treat adults with glaucoma, according to a Bloomberg report on Thursday. The shares of Aliso Viejo, Cal...
2023-06-07 15:40:43 ET Glaukos intraocular implant gets FDA review Celanese to provide VitalDose drug delivery tool for Glaukos' eye implant For further details see: Glaukos upgraded to overweight by Piper Sandler ahead of product launches
Enrollment Completion Achieved in Less Than Six Months from Trial Commencement, Ahead of Original Timing Expectations Phase 3 Confirmatory Trial Results Together with Already-Completed First Phase 3 Trial Expected to Support Glaukos’ Targeted NDA Submission for Epioxa by the End of...
2023-05-30 17:00:54 ET Summary Sight Sciences, Inc.'s share price has fallen by -13.3% in the past 3 weeks, despite reporting a narrower-than-expected net loss in Q1 and sticking to its 2023 guidance. Sight Sciences' key Q1 2023 metrics offered positive read-throughs for the compa...
News, Short Squeeze, Breakout and More Instantly...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...
2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...